GRI BIO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 USD | -0.05% |
|
-6.52% | -84.04% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.74M |
|---|---|---|---|---|---|
| Net income 2022 | -3M | Net income 2023 | -13M | EV / Sales 2022 * | - |
| Net Debt 2022 | 664K | Net cash position 2023 | 1.79M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.1
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95.82% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.05% | ||
| 1 week | -6.52% | ||
| Current month | -43.42% | ||
| 1 month | -43.42% | ||
| 3 months | -83.92% | ||
| 6 months | -94.61% | ||
| Current year | -84.04% |
1 week
0.41
0.46
1 month
0.410.78
Current year
0.415.00
1 year
0.4162.23
3 years
0.4193.31
5 years
0.4193.31
10 years
0.4193.31
| Managers | Title | Age | Since |
|---|---|---|---|
W. Hertz
CEO | Chief Executive Officer | 54 | 23-03-31 |
Leanne Kelly
DFI | Director of Finance/CFO | 47 | 23-04-24 |
| Chief Tech/Sci/R&D Officer | 64 | 23-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Baker
BRD | Director/Board Member | 60 | - |
Roelof Rongen
BRD | Director/Board Member | 59 | 23-04-23 |
David Szekeres
CHM | Chairman | 50 | 23-04-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.4301 | +0.02% | 77,682 |
| 24-04-26 | 0.43 | -0.05% | 62,259 |
| 24-04-25 | 0.4302 | -1.65% | 25,078 |
| 24-04-24 | 0.4374 | -2.13% | 118,053 |
| 24-04-23 | 0.4469 | -2.85% | 143,359 |
End-of-day quote Nasdaq, April 25, 2024
More quotes
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| -84.04% | 1.37M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- GRI Stock
